Blogs

CU Cancer Center News and Stories

Immunotherapy

Head and Neck Cancer    Cancer    Oncology    Immunotherapy

Selective Nodal Radiation May Be a More Effective Approach in Cancer Treatment

A promising new study released by the University of Colorado Cancer Center suggests that recurrence of certain cancers can be significantly decreased by irradiating only a select set of lymph nodes near a tumor rather than all of them.


Author Laura Kelley | Publish Date November 16, 2022
Full Story

Ovarian Cancer    Immunotherapy    Genetics

Innovative Immunotherapy Treatment Helps Ovarian Cancer Patient See Amazing Results

People often tell Winona Williams that she’s brave, and she is. Ovarian cancer could easily become a dark cloud over her, shadowing every minute of every day.


Author Rachel Sauer | Publish Date September 20, 2022
Full Story

Research    Immunotherapy    lymphoma

Research Shows CAR T Cell Therapy Is Effective Second-Line Treatment for Large B-Cell Lymphoma

Large B-cell lymphoma (LBCL) is one of the most aggressive lymphomas and accounts for about 30% of all lymphoma diagnoses.


Author Rachel Sauer | Publish Date July 14, 2022
Full Story

Research    Lung Cancer    Immunotherapy

CU Cancer Center Researcher Focusing on Multiple Avenues of Immunoprevention for Lung Cancer

An exciting and innovative area of cancer research is immunoprevention, in which studies focus on preventing cancer before its onset by using vaccines, antibodies, and other immune mechanisms.


Author Rachel Sauer | Publish Date July 06, 2022
Full Story

Patient Care    Lung Cancer    Prostate Cancer    Melanoma    Immunotherapy   

Acknowledging the Fears of Cancer by Giving Them a Face and a Name

To understand why Beau Gill built a mental cupboard for Jeff and Spike, first you must travel back with him to the small town of Catemaco in Mexico’s state of Veracruz.


Author Rachel Sauer | Publish Date April 20, 2022
Full Story

Immunotherapy

Immunotherapy and HDAC inhibition are anti-cancer besties

Immunotherapies have revolutionized the care of many cancers, teaching the body’s own immune cells to recognize and attack tumor cells. Leading the way are drugs known as checkpoint inhibitors, which block a kind of “white flag” that tumors wave as a peace signal to T cells that would very much like to kill them. Really, this white flag is a protein called PD-L1 – many tumors coat themselves in it. When PD-L1 on the surface of a cancer cell sees its partner, PD1, on T cells, these T cells are tricked into letting the cancer cell live. To counteract this dirty trick, checkpoint inhibitor drugs block the functions of PD-L1 on tumor cells (e.g. atezolizumab) or PD1 on T cells (e.g. pembrolizumab), allowing T cells to go about their cancer-killing business.


Author Cancer Center | Publish Date June 24, 2019
Full Story

Melanoma    Immunotherapy

Is your melanoma hot enough for immunotherapy?

Melanomas tend to be “hot” or “cold” – if they’re hot, immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50 percent of melanomas are cold, making them invisible to the immune system, and patients with cold tumors tend to show little benefit from immunotherapies. The problem is that it’s been impossible to distinguish a hot melanoma from a cold one – the solution has been to administer immunotherapy and hope for the best, often leading to wasted time and resources. Now a University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 identifies a possible way to predict which melanomas are hot and cold: Tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.


Author Cancer Center | Publish Date April 02, 2019
Full Story

CU Cancer Center In the News

Targeted Oncology

Forsberg Explains How Selinexor Fits Into Sequencing Therapies in R/R Multiple Myeloma

news outletTargeted Oncology
Publish DateNovember 16, 2022

During a roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.

Full Story
Cancer Health

Pancreatic Cancer Survivor Shares a Message of Hope

news outletCancer Health
Publish DateNovember 15, 2022

November is Pancreatic Cancer Awareness Month. Laura Foote shares her story to bring hope and express gratitude.

Full Story
TIME

How Bladder Cancer Differs in Women and Younger Adults

news outletTIME
Publish DateNovember 15, 2022

Men are three to four times more likely than women to develop bladder cancer, but the disease tends to be deadlier in females. Why?

Full Story
Biospace

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

news outletBiospace
Publish DateNovember 14, 2022

New therapeutic addresses need in patients suffering with cold and refractory tumors.

Full Story